SHARE

France, Innovation, 2017

Telomium continues to develop their product

15th July 2019

Telomium, one of the winners of the French Innovation Journey from Education to Business

After applying the vaccine to three monkeys without secondary reactions, Telomium continues to develop their immunotherapy product against cancer.

Telomium is a biotechnology company developing a therapeutic product for cancer immunotherapy. Their first-in-class ribonucleoprotein vaccine has the ability to mimic a viral attack and induce an auto-immune reaction targeted against any form of cancer, without causing significant side effects. This self-vectored and self-adjuvanted vaccine is prepared from a patented, safe, competitive and scalable yeast-based technology using a breakthrough innovation in the production of recombinant telomerase.

After defining the best use of their product, Telomium plans to raise founds in order so start their regular preclinical development then performing clinical trials in humans and setting a deal with a big pharma group

Venture Centre of Excellence launches call for VCs to join

Venture Centre of Excellence launches call for VCs to join

Partnership with EIT Health will finance start-ups

Find out more

EIT Health and EIC collaboration edges closer

EIT Health and EIC collaboration edges closer

Pair close in on partnership

Find out more

EIT Health expands to Finland as HUS becomes partner

EIT Health expands to Finland as HUS becomes partner

The country's largest healthcare provider

Find out more